CLAIMS

1. Combination composition comprising as active ingredients L-carnitine or ~~a derivative~~ propionyl L-carnitine or a salt thereof, troxerutine, diosmine, hesperidine, and optionally one or more excipient pharmaceutically acceptable.

~~2. Combination composition of claim 1 in which the derivative of L carnitine is propionyl L carnitine.~~

~~3~~2. The ~~C~~combination composition of claim 1~~ or 2~~, which comprises:
- L-carnitine or propionyl L-carnitine, in a dose of from 10 to 3000 mg, preferred doses is of from 50 mg to 400 mg, the most preferred dose is 136 mg;

- troxerutine, in a dose of from 900 mg to 50 mg, preferred doses is of from 400 mg to 200 mg, the most preferred dose is 300 mg;

- diosmine, in a dose of from 900 mg to 50 mg, preferred doses is of from 400 mg to 200 mg, the most preferred dose is 300 mg; and

- hesperidine in a dose of from 10 mg to 500 mg, preferred doses is of from 50 mg to 200 mg, the most preferred dose is 100 mg.

~~4~~3. The ~~C~~combination composition of claim 1, as a dietary supplement.

~~5~~4. The ~~C~~combination composition of claim 1, as a medicament.

~~6~~5. The ~~C~~combination composition of claim 1, further comprising coenzymes, mineral substances, antioxidants, vitamins, anticloting agents, and agents useful for treating diseases of the veins.

~~7~~6. The ~~C~~combination composition of claim 1 or 2, for use ~~for~~ in the prevention or treatment of diseases of the veins.

~~8~~7. Use of a combination composition comprising as active ingredients L-carnitine or ~~a derivative~~ propionyl L-carnitine or a salt thereof, troxerutine, diosmine and hesperidine, for preparing a medicament for the prevention or treatment of diseases of the vein.

~~9. Use according to claim 8 in which the derivative of L carnitine is propionyl L carnitine.~~

~~10~~8. The ~~U~~use according to claim ~~8 or 9~~ 7, in which the disease of the veins is selected from the group consisting of: chronic venous insufficiency, chronic venous disease and complication thereof.

~~11~~9. The ~~U~~use according to claim ~~10~~ 8, in which said complication is selected from the group consisting of: swelling and inflammation of veins in the rectum, anus and vulva; venous hypertension; increased permeability; oedema; capillary damage; skin changes; venous leg ulcers; swelling ankles; heavy legs; varicose veins; swelling leg; ulcers; vein thrombosis; phlebitis; thrombo-phlebitis; pulmonary embolus or hemorrhoids.

~~12~~10. The ~~U~~use according to claim ~~8 or 9~~ 7, in which the salt of L-carnitine or propionyl L-carnitine is selected from the group consisting of: chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate and acid tartrate, glycerophosphate, mucate, magnesium tartrate, 2-amino-ethanesulphonate, magnesium 2-amino-ethanesulphonate, methanesulphonate, choline tartrate, trichloroacetate, or trifluoroacetate.

~~13~~11. The ~~U~~use according to claim ~~8 or 9~~ 7, for oral, parenteral, intravenous, topical and/or transdermal administration.

~~14~~12. The ~~U~~use according to claim ~~8 or 9~~ 7, for oral administration.